Skip to main content
SpringerLink
Log in

New Governmental Regulatory System for Stem Cell—Based Therapies in Japan

  • Global Perspective
  • Published:
Therapeutic Innovation & Regulatory Science Aims and scope Submit manuscript

Abstract

Regenerative medicine using stem cells is expected to provide tools for the replacement or repair of damaged tissues, opening up the possibility of treating many diseases that cannot otherwise be effectively treated. To promote the development of and access to regenerative medicine, it is important to take a balance of expedited provision of innovative therapies and appropriate steps to ensure safety and efficacy. While most developed countries have various regulatory frameworks for clinical trials and medical treatments involving stem cells, the Act on the Safety of Regenerative Medicine and the Revised Pharmaceutical Affairs Law have recently been simultaneously passed by the Japanese Diet. According to the former act, these medical technologies are categorized into 3 classes depending on their anticipated potential risk to human health, and the specific procedures falling into each class are determined. In addition, the act enables medical institutions to commission cell processing by business facilities outside the institution (even foreign facilities) that fulfill the requirements set out by the Ministry of Health, Labour and Welfare, with the aim to promote collaboration between academia and industry from an early stage. According to the latter law, a therapeutic product for regenerative medicine is defined as a product distinct from pharmaceuticals and medical devices, enabling regenerative medical products to be given a conditional, time-limited marketing authorization much earlier than that under the previous system. The new legal framework of regenerative medicine is expected to achieve the aim to develop and promote regenerative medicine, aiming at timely provision of safe and effective therapies and products.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131:861–872.

    Article  CAS  Google Scholar 

  2. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310:2191–2194.

    Article  Google Scholar 

  3. Regenerative Medicine Promotion Law [in Japanese]. Law No. 13. http://law.e-gov.go.jp/cgi-bin/idxselect.cgi?IDX_OPT=1&H_NAME=%8d%c4%90%b6%88%e3%97%c3&H_NAME_YOMI=%82%a0&H_NO_GENGO=H&H_NO_YEAR=&H_NO_TYPE=2&H_NO_NO=&H_FILE_NAME=H25HO013&H_RYAKU=1&H_CTG=1&H_YOMI_GUN=1&H_CTG_GUN=1. Published May 10, 2013.

  4. Pharmaceutical Affairs Law [in Japanese]. Law No. 145. http://law.e-gov.go.jp/cgi-bin/idxselect.cgi?IDX_OPT=1&H_NAME=%96%f2%8e%96%96%40&H_NAME_YOMI=%82%a0&H_NO_GENGO=H&H_NO_YEAR=&H_NO_TYPE=2&H_NO_NO=&H_FILE_NAME=S35HO145&H_RYAKU=1&H_CTG=1&H_YOMI_GUN=1&H_CTG_GUN=1. Published August 10, 1960.

  5. Unknown territory [editorial]. Nature. 2013;494:5.

    PubMed  Google Scholar 

  6. Cyranoski D. Korean deaths spark inquiry. Nature. 2010;468;485.

    Article  CAS  Google Scholar 

  7. Act on the Safety of Regenerative Medicine [in Japanese]. Act No. 85. http://www.mhlw.go.jp/file/06-Seisakujouhou-10800000-Iseikyoku/0000030847.pdf. Published November 27, 2013.

  8. Pharmaceuticals, Medical Devices, and Other Therapeutic Products Act [in Japanese]. Law No. 84. http://www.mhlw.go.jp/topics/bukyoku/soumu/houritu/dl/183-55.pdf. Published November 27, 2013.

  9. Medical Practitioners’ Act [in Japanese]. Act No. 201. http://law.e-gov.go.jp/cgi-bin/idxselect.cgi?IDX_OPT=1&H_NAME=%88%e3%8e%74%96%40&H_NAME_YOMI=%82%a0&H_NO_GENGO=H&H_NO_YEAR=&H_NO_TYPE=2&H_NO_NO=&H_FILE_NAME=S23HO201&H_RYAKU=1&H_CTG=1&H_YOMI_GUN=1&H_CTG_GUN=1. Published July 30, 1948.

  10. Medical Service Act [in Japanese]. Act No. 205. http://law.e-gov.go.jp/cgi-bin/idxselect.cgi?IDX_OPT=1&H_NAME=%88%e3%97%c3%96%40&H_NAME_YOMI=%82%a0&H_NO_GENGO=H&H_NO_YEAR=&H_NO_TYPE=2&H_NO_NO=&H_FILE_NAME=S23HO205&H_RYAKU=1&H_CTG=1&H_YOMI_GUN=1&H_CTG_GUN=1. Published July 30, 1948.

  11. Cyranoski D. Stem cells cruise to clinic. Nature. 2013;494:413.

    Article  CAS  Google Scholar 

  12. Food and Drug Administration. CFR: Code of Federal Regulations title 21. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=1271&showFR=1&subpartNode=21:8.0.1.5.55.1. Accessed January 8, 2014.

  13. European Medicines Agency. Regulation (EC) No. 1394/2007 of the European Parliament and of the Council of 13 November 2007 on advanced therapy medicinal products and amending directive 2001/83/EC and regulation (EC) No. 726/2004. http://ec.europa.eu/health/files/eudralex/vol-1/reg_2007_1394/reg_2007_1394_en.pdf. Accessed December 20, 2013.

  14. Pharmaceuticals and Medical Devices Agency. Relief services for adverse health effects. http://www.pmda.go.jp/english/service/outline_r.html. Accessed November 27, 2013.

  15. Halme DG, Kessler DA. FDA regulation of stem-cell-based therapies. N Engl J Med. 2006;355:1730–1735.

    Article  CAS  Google Scholar 

  16. Office for Human Research Protections. IRBs and assurances. http://www.hhs.gov/ohrp/assurances/index.html. Accessed January 8, 2014.

  17. Health Research Authority. National Research Ethics Service (NRES). http://www.hra.nhs.uk/about-the-hra/our-committees/nres/. Accessed January 8, 2014.

  18. European Medicines Agency. Guideline on safety and efficacy follow-up: risk management of advanced therapy medicinal products (EMEA/149995/2008). http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2009/10/WC500006326.pdf. Accessed January 8, 2014.

  19. Food and Drug Administration. Proposed approach to regulation of cellular and tissue-based products (97N-0068). http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Tissue/UCM062601.pdf. Accessed January 8, 2014.

  20. Hamburg MA. Shattuck lecture: innovation, regulation, and the FDA. N Engl J Med. 2010;363:2228–2232.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Office for Promotion of Regenerative Medicine, Research and Development Division, Health Policy Bureau, Ministry of Health, Labour and Welfare, 1-2-2 Kasumigaseki, Chiyoda-ku, Tokyo, 100-8916, Japan

    Akinori Hara MD, PhD

  2. Pharmaceuticals and Medical Devices Agency, Tokyo, Japan

    Daisaku Sato PhD

  3. Health Policy Bureau, Ministry of Health, Labour and Welfare, Tokyo, Japan

    Yasuyuki Sahara MD, MPH

Authors
  1. Akinori Hara MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daisaku Sato PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yasuyuki Sahara MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Akinori Hara MD, PhD.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hara, A., Sato, D. & Sahara, Y. New Governmental Regulatory System for Stem Cell—Based Therapies in Japan. Ther Innov Regul Sci 48, 681–688 (2014). https://doi.org/10.1177/2168479014526877

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1177/2168479014526877

Keywords

Search

Navigation